Raloxifene and Warfarin Interaction

Understanding the Raloxifene and Warfarin Interaction

FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Raloxifene belongs to the Selective Estrogen Receptor Modulator (SERM) class and Warfarin belongs to the Vitamin K Antagonist (Anticoagulant) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Raloxifene can affect how warfarin thins your blood, which might change your risk of bleeding or blood clots. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Raloxifene has 7 total documented interactions on file in this dataset, and Warfarin has 163. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor should monitor your blood clotting tests more closely when you start or stop taking raloxifene. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Raloxifene or Warfarin based on a web page, speak with your prescriber or pharmacist before making any change.